The Androgenic Ovarian Syndrome (SOA) is a hyperandrogenic state in women that ends in morphological changes of ovarian micropoliquistosis (mPCO) It is known that obesity is associated with SOA, but its causal role in this condition it has not yet been determined. The proportion of women with SOA who are overweight but non-obese varies from 10% in Italy to 37% in Kuwait. The The highest prevalence of obesity is reported in studies conducted in the United States and Australia, with 61% to 76% of women with SOA considered obese. Women with PCOS are more likely to have fat on the upper side with a higher waist-to-hip ratio than controls and abdominal or visceral adiposity is associated with increased insulin resistance, which could exacerbate metabolic and reproductive abnormalities in the SOA Explaining the physiopathological mechanisms of both Dyslipidemia and obesity in patients with Androgenic Ovarian Syndrome we can already find in these patients two of the five key aspects for the diagnosis of the metabolic syndrome which is common to find in these patients. Different studies have shown that these changes in patients with Androgenic Ovarian Syndrome cause them to be at higher risk of cardiovascular event and diabetes, secondary to the endothelial lesion caused by dyslipidemia and hyperglycemia. This is an important reason why not only must the diagnosis of SOP / SOA be made, but it must be treated to avoid this consequence in later years.